Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095254 | 0.92 | TLR8 (0.63) | TLR8TLR7 | |
| SCHEMBL7505418 | 0.91 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL1094090 | 0.87 | TLR8 (0.52) | TLR8TLR7 | |
| SCHEMBL1104739 | 0.85 | TLR8 (0.56) | TLR8TLR7 | |
| SCHEMBL1095621 | 0.83 | TLR8 (0.39) | TLR8TLR7 | |
| SCHEMBL1093894 | 0.83 | TLR8 (0.45) | TLR8TLR7 | |
| SCHEMBL7505947 | 0.83 | TLR8 (0.71) | TLR8TLR7 | |
| SCHEMBL10044372 | 0.82 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL1095467 | 0.81 | TLR8 (0.46) | TLR8TLR7 | |
| SCHEMBL7515942 | 0.80 | TLR8 (0.55) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | claimed |
| EP-3081558-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Array Biopharma, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-8304407-B2 | 8-substituted benzoazepines as toll-like receptor modulators | ARRAY BIOPHARMA INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120165317-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153622-B2 | modulating a patient's immune system; treating autoimmunity, inflammation allergy, asthma, transplant rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency; (1E,4E)-ethyl 2-amino-8-(perfluoroethyl)-3H-benzo[b]azepine-4-carboxylate; antiinflammatory, anticarcinogenic agents | ARRAY BIOPHARMA INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153622-B2 | modulating a patient's immune system; treating autoimmunity, inflammation allergy, asthma, transplant rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency; (1E,4E)-ethyl 2-amino-8-(perfluoroethyl)-3H-benzo[b]azepine-4-carboxylate; antiinflammatory, anticarcinogenic agents | ARRAY BIOPHARMA INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2007024612-A2 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165317-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR7, TLR9 | TLR8 1/4885TLR7 2/4885 |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR7, TLR9 | TLR8 1/4885TLR7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.